Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 245

Sort by

Sort Order Select

Journal Articles

An ounce of which prevention is worth a…?

Joerg Halter, Jakob Passweg

Blood (2021) 137 (14): 1852–1853.

https://doi.org/10.1182/blood.2021010688

Published: 2021

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen-Huan Hu, Mary M. Horowitz, Marcie L. Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel-Angel Perales, Marcelo C. Pasquini

Blood (2020) 136 (1): 137–139.

https://doi.org/10.1182/blood.2020006216

Published: 2020

Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan

Blood (2020) 135 (25): 2316–2319.

https://doi.org/10.1182/blood.2019004602

Published: 2020

Includes: Supplemental data

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

The earlier the better: timely mitigation of CRS

Rayne H. Rouce

Blood (2019) 134 (24): 2119–2120.

https://doi.org/10.1182/blood.2019003618

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Caixia Li, Changfeng Zhang, PhD, Xiaochen Chen, Ying Zhang, Jia Chen, MD, Liqing Kang, Xiaoyan Lou, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5313.

https://doi.org/10.1182/blood-2019-126821

Published: 2019

Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD

Blood (2019) 134 (Supplement_1): 5617.

https://doi.org/10.1182/blood-2019-131799

Published: 2019

Journal Articles

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Zunairah Shah, MBBS, Syeda Sabeeka Batool, MBBS, MD, Hafiz Muhammad Fazeel, MBBS, Mustafa Nadeem Malik, MD, Maryam Sadiq, MBBS, Syeda Fatima Hassan, MBBS, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Nisma Javed, MBBS, Aqsa Ashraf, MD, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Marium Ghani, MBBS, Arshia Akbar, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5597.

https://doi.org/10.1182/blood-2019-131849

Published: 2019

Journal Articles

Tocilizumab for Prophylaxis of Cytokine Release Syndrome after Outpatient-Based Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation

Oscar Marquez, MD, Andrés Gómez-De León, MD, Perla R. Colunga Pedraza, MD, Cesar O Pezina Cantú, MD, Diana E Garcia-Camarillo, MD, Paola Santana-Hernandez, MD, Cesar Homero Gutierrez-Aguirre, PhD, David Gomez-Almaguer, MD

Blood (2019) 134 (Supplement_1): 5624.

https://doi.org/10.1182/blood-2019-132088

Published: 2019

Journal Articles

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Ping Li, Lili Zhou, Shiguang Ye, Shaoguang Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 5625.

https://doi.org/10.1182/blood-2019-130119

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Journal Articles

Haploidentical Stem Cell Transplantation with TCR Alpha/Beta and CD19 Depletion in Adult Patients with Hematological Malignancies

Maria V. Dovydenko, MD PhD, Elena N. Parovichnikova, MD PhD, Larisa A. Kuzmina, MD PhD, Vera A. Vasilyeva, MD PhD, Mikhail Yu. Drokov, MD PhD, Olga M. Koroleva, MD, Ekaterina D. Mikhaltsova, MD PhD, Natalia N. Popova, MD, Zoya V. Konova, Anna A. Dmitrova, MD, Ulyana V. Maslikova, MD, Olga S. Starikova, MD, Tatiana V. Gaponova, MD PhD, Denis V. Kamelskih, MD, Michael Maschan, MDMSc, Valeriy G. Savchenko, MD PhD

Blood (2019) 134 (Supplement_1): 5648.

https://doi.org/10.1182/blood-2019-131316

Published: 2019

Journal Articles

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

Alexander Slota, MD, Roomana Khan, MD, Akhil Rahman, MD, Eiran A Warner, MD

Blood (2019) 134 (Supplement_1): 5630.

https://doi.org/10.1182/blood-2019-127586

Published: 2019

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

NARROW

An ounce of which prevention is worth a…?

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

DARTs point the way forward in AML

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

The earlier the better: timely mitigation of CRS

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Tocilizumab for Prophylaxis of Cytokine Release Syndrome after Outpatient-Based Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Haploidentical Stem Cell Transplantation with TCR Alpha/Beta and CD19 Depletion in Adult Patients with Hematological Malignancies

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only